MétaCan
Menu
Back to cohort
Record W2622731939 · doi:10.1002/hon.2438_53

A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT <scp>S</scp>ELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE <scp>B</scp>‐CELL LYMPHOMA (<scp>DLBCL</scp>)

2017· article· en· W2622731939 on OpenAlexaff
R. Casasnovas, Jason R. Westin, Catherine Thiéblemont, Josée M. Zijlstra, Brian T. Hill, Fátima de la Cruz Vicente, Sylvain Choquet, Paolo F. Caimi, Jason Kaplan, Miguel Canales, John Kuruvilla, George Follows, Eric Van Den Neste, J. Meade, Brendan Wrigley, Marissa Devlin, Jean-Richard Saint-Martin, Conny Nippgen, Humphrey Gardner, Sharon Shacham, Michael Kauffman, Marie Maerevoet

Bibliographic record

VenueHematological Oncology · 2017
Typearticle
Languageen
FieldMedicine
TopicCNS Lymphoma Diagnosis and Treatment
Canadian institutionsPrincess Margaret Cancer Centre
Fundersnot available
KeywordsNeutropeniaMedicineInternal medicineNauseaAdverse effectDiffuse large B-cell lymphomaPhases of clinical researchAnemiaRefractory (planetary science)GastroenterologyVomitingLymphomaFebrile neutropeniaOncologyToxicityBiology

Abstract

fetched live from OpenAlex

Introduction: Patients (pts) with persistent DLBCL after two lines of therapy have limited effective treatment options. The nuclear export protein exportin 1 (XPO1) is upregulated in hematologic malignancies, including DLBCL. Selinexor (SEL), an oral XPO1 inhibitor, causes sequestration of tumor suppressor proteins including p53, p21, and IkBa, the latter of which serves to suppress NF-kB-driven transcription, along with reductions in c-Myc and Bcl family proteins. In a phase I clinical study pts with relapsed/refractory (R/R) DLBCL treated with SEL, an overall response rate (ORR) of 32% including 4 CRs was shown. Methods: Pts with R/R DLBCL were randomized to 60 or 100 mg of SEL twice weekly (8 doses) per 28-day cycle. Pts were also stratified by DLBCL subtype (GCB or non-GCB). The primary objectives are to determine the ORR, and safety of 60 v 100 mg doses. Disease response was assessed by an Independent Central Radiological Review (ICRR), using the Lugano Classification (Cheson, 2014). Pt tissue samples were also collected to evaluate cytogenetics. Results: 72 pts were enrolled: 37 pts on 60 mg and 35 pts on 100 mg. Both groups had a median of 3 prior treatment regimens. The most common related Grade 1/2 adverse effects (AEs) were fatigue (47%), nausea (46%), anorexia (42%), and vomiting (33%). Common Grade 3/4 AEs were thrombocytopenia (39%), fatigue (18%), neutropenia (18%), and anemia (13%). They were managed with dose interruption/reduction, platelet stimulators, and/or standard supportive care. Grade 3/4 fatigue (26% v 11%) and thrombocytopenia (46% v 32%) were higher in 100 mg arm as compared to the 60 mg arm. Among the 63 evaluable pts, the ICRR determined ORR was 28.5% (Table 1). Nine responders, including 6 CR, remain on treatment. Responders on the 60 mg arm have a median time on treatment of 8.9 months as compared to 3.8 months on the 100 mg arm. Evaluation of molecular predictors of response is currently ongoing including investigation of translocations in c-Myc and Bcl proteins as well as targeted sequencing for alterations in genes commonly mutated in B-cell malignancies. Conclusion: SEL monotherapy shows activity in pts with R/R DLBCL including in pts with GCB subtype. 60 mg SEL twice weekly was more tolerable than 100 mg twice weekly, with fewer dosing interruptions due to toxicity. Objective responses to SEL were durable at 60 mg BIW, suggesting these responses were associated with clinical benefit. Molecular predictors of response are being evaluated. Keywords: diffuse large B-cell lymphoma (DLBCL); NF-kB; non-Hodgkin lymphoma (NHL)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.010
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.756
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.010
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0040.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.001
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.028
GPT teacher head0.305
Teacher spread0.277 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueHematological OncologySame topicCNS Lymphoma Diagnosis and TreatmentFrench-language works237,207